Join to View Full Profile
20 York Street Smilow Cancer Hospital Yale New HavenLower LevelNew Haven, CT 06510
Phone+1 203-200-2100
Fax+1 203-785-4622
Dr. Bindra is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Memorial Sloan Kettering Cancer CenterResidency, Radiation Oncology, 2008 - 2012
Yale School of MedicineClass of 2007
Certifications & Licensure
CT State Medical License 2012 - 2026
NJ State Medical License 2014 - 2019
NY State Medical License 2008 - 2012
American Board of Radiology Radiation Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2014-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014-2017
Clinical Trials
- TAU-2014-1: Mibefradil and Hypofractionated Re-Irradiation Therapy in Recurrent GBM Start of enrollment: 2014 Aug 01
- BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations Start of enrollment: 2020 Feb 16
Publications & Presentations
PubMed
- Mismatch repair deficiency drives malignant progression and alters the tumor immune microenvironment in glioblastoma models.Montserrat Puigdelloses Vallcorba, Nishant Soni, Seung-Won Choi, Kavita Rawat, Tanvi Joshi
The Journal of Clinical Investigation. 2026-03-16 - 1 citationsTargeted CRISPR knockout screening identifies known and novel chemogenomic interactions between DNA damaging agents and DNA repair genes.Collin D Heer, James L Elia, Vijay Menon, Spenser S Johnson, Sofia R Arbelaez
NAR Cancer. 2026-03-01 - Phase I/II and window-of-opportunity study of pamiparib and metronomic temozolomide for recurrent isocitrate dehydrogenase mutant gliomas.David Schiff, Xiaobu Ye, Jing Li, Benjamin M Ellingson, Patrick Y Wen
Neuro-Oncology. 2026-02-01
Journal Articles
- Krebs-Cycle-Deficient Hereditary Cancer Syndromes Are Defined by Defects in Homologous-Recombination DNA RepairBrian Shuch, Ranjit S Bindra, Christopher D Corso, Peter M Glazer, Nature
Abstracts/Posters
- PARP Inhibitors Are Effective in IDH1/2 Mutant MDS and AML Resistant to Targeted IDH InhibitorsRanjit Bindra, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. a Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Mye...Ranjit Bindra, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
Farmington Man with Dangerous Brain Tumor Grateful for Second OpinionMarch 10th, 2026- Yale Spinout Modifi Biosciences Acquired by MerckOctober 23rd, 2024
- Researchers Create 'Chameleon' Compound That Targets Drug-Resistant Brain CancersJune 3rd, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
